

Anti-Complement C5 Reference Antibody (ravulizumab) Recombinant Antibody Catalog # APR10082

Specification

Anti-Complement C5 Reference Antibody (ravulizumab) - Product Information

Application Primary Accession Reactivity Clonality Isotype Calculated MW FC, E, FTA <u>P01031</u> Cynomolgus, Human, Mouse Monoclonal IgG2SA 145.8 KDa

Anti-Complement C5 Reference Antibody (ravulizumab) - Additional Information

Target/Specificity Complement C5

Endotoxin < 0.001EU/ μg,determined by LAL method.

Conjugation Unconjugated

Expression system CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-Complement C5 Reference Antibody (ravulizumab) - Protein Information

Name C5

Synonyms CPAMD4

Function

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

Cellular Location Secreted.


Anti-Complement C5 Reference Antibody (ravulizumab) - Protocols




Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

Anti-Complement C5 Reference Antibody (ravulizumab) - Images




Anti-Complement C5 Reference Antibody (ravulizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Complement C5 Reference Antibody (ravulizumab)is more than 98.96% ,determined by SEC-HPLC.





Immobilized human C5 His at 2 $\,\mu\text{g/mL}$ can bind Anti-Complement C5 Reference Antibody (ravulizumab)]]EC50=0.00552 $\,\mu\text{g/mL}$